Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prion-protein-specific aptamer reduces PrPSc formation.

Daniela Proske1, Sabine Gilch, Franziska Wopfner

  • 1Institut für Biochemie, Genzentrum der LMU München, Feodor-Lynen-Strasse 25, 81377 München (Germany).

Chembiochem : a European Journal of Chemical Biology
|August 31, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Neuronal Cell Line Model for Studying Camel Prions.

Pathogens (Basel, Switzerland)·2026
Same author

Limited transmission of cervid prions to nonhuman primates provides insights into the zoonotic potential of chronic wasting disease.

Science advances·2026
Same author

Optimising DNA origami assembly by reducing off-target interactions.

Nature communications·2026
Same author

Prion shedding is reduced by chronic wasting disease vaccination.

PLoS pathogens·2026
Same author

Selection and Characterization of SARS-CoV-2 Spike Binding Clickmers.

Chembiochem : a European journal of chemical biology·2026
Same author

Prion shedding is reduced by chronic wasting disease vaccination.

bioRxiv : the preprint server for biology·2025
Same journal

Sustainable Synthesis of Bio-Based Furanic and Aromatic Amines Using an Optimized Whole-Cell Transaminase-Decarboxylase Cascade in E. coli RARE.

Chembiochem : a European journal of chemical biology·2026
Same journal

Composite Dissolvable Microneedle-Enabled Local High-Dose Delivery of Endogenous Thiols for Efficient Allergic Dermatitis Treatment.

Chembiochem : a European journal of chemical biology·2026
Same journal

Revisiting the Radical Quenching Activity of Ebselen Analogues in Homogeneous Phase and In Silico Anti-ferroptotic Activity with Histone Deacetylase.

Chembiochem : a European journal of chemical biology·2026
Same journal

Reaction Optimization for Enzymatic Deconstruction of Industrially Relevant Nylon Composites.

Chembiochem : a European journal of chemical biology·2026
Same journal

Deploying Artificial Metalloenzymes in Complex Environments: Strategies and Applications.

Chembiochem : a European journal of chemical biology·2026
Same journal

Synthetic Ligands of Myeloid C-Type Lectin Receptors.

Chembiochem : a European journal of chemical biology·2026
See all related articles

Researchers developed RNA aptamers that target the prion protein, reducing the formation of disease-causing aggregates in prion diseases. This discovery offers a potential new therapeutic strategy for treating these neurodegenerative conditions.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Molecular Biology

Background:

  • Transmissible spongiform encephalopathies (TSEs) are linked to the misfolding of cellular prion protein (PrP(C)) into an abnormal, aggregated isoform (PrP(Sc)).
  • PrP(Sc) aggregates are protease-resistant and accumulate in the central nervous system, driving TSE pathogenesis.

Purpose of the Study:

  • To develop novel therapeutic agents targeting the prion protein conversion process.
  • To investigate the potential of RNA aptamers in inhibiting the formation of pathogenic PrP(Sc).

Main Methods:

  • Selection of nuclease-resistant RNA aptamers targeting a specific peptide region (residues 90-129) of the human prion protein.
  • Characterization of aptamer binding specificity to full-length prion proteins from human, mouse, and hamster.

Related Experiment Videos

  • Assessment of aptamer DP7's effect on de novo synthesized PrP(Sc) in prion-infected neuroblastoma cells.

    • Main Results:

    • RNA aptamer DP7 specifically recognizes a functionally important domain of the prion protein, conserved across species.
    • Low concentrations of aptamer DP7 significantly reduced the proportion of newly synthesized protease K-resistant PrP(Sc) within 16 hours in infected cells.
    • The aptamer demonstrated efficacy in reducing pathogenic prion protein in a cellular model.

    Conclusions:

    • RNA aptamers targeting the prion protein represent a promising new class of molecules for TSE therapy.
    • Aptamer DP7 shows potential for the development of drugs for prion disease treatment and prevention.
    • Targeting the PrP(C) to PrP(Sc) conversion is a viable strategy for combating prion diseases.